280 related articles for article (PubMed ID: 19640613)
1. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
[TBL] [Abstract][Full Text] [Related]
2. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
[TBL] [Abstract][Full Text] [Related]
3. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore modelling and virtual screening for identification of new Aurora-A kinase inhibitors.
Deng XQ; Wang HY; Zhao YL; Xiang ML; Jiang PD; Cao ZX; Zheng YZ; Luo SD; Yu LT; Wei YQ; Yang SY
Chem Biol Drug Des; 2008 Jun; 71(6):533-9. PubMed ID: 18410307
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5).
Li X; Wang L; Long L; Xiao J; Hu Y; Li S
Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY
Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425
[TBL] [Abstract][Full Text] [Related]
8. Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors.
Gellibert F; Fouchet MH; Nguyen VL; Wang R; Krysa G; de Gouville AC; Huet S; Dodic N
Bioorg Med Chem Lett; 2009 Apr; 19(8):2277-81. PubMed ID: 19285388
[TBL] [Abstract][Full Text] [Related]
9. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK
Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M
Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945
[TBL] [Abstract][Full Text] [Related]
12. Screening and identification of a novel class of TGF-β type 1 receptor kinase inhibitor.
Huynh QK; Wise SJ; Koch KA; Castonguay LA; Reid BG; Pagratis EE; Koditek D; Glascock CB; Pitts KR; Turner BA; Liu X; Hung M; Han B; Pagratis N
J Biomol Screen; 2011 Aug; 16(7):724-33. PubMed ID: 21521800
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
Kim DK; Jang Y; Lee HS; Park HJ; Yoo J
J Med Chem; 2007 Jun; 50(13):3143-7. PubMed ID: 17552507
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and evaluation of small molecule imidazo[2,1-b][1,3,4]thiadiazoles as inhibitors of transforming growth factor-β type-I receptor kinase (ALK5).
Patel HM; Sing B; Bhardwaj V; Palkar M; Shaikh MS; Rane R; Alwan WS; Gadad AK; Noolvi MN; Karpoormath R
Eur J Med Chem; 2015 Mar; 93():599-613. PubMed ID: 25234355
[TBL] [Abstract][Full Text] [Related]
15. Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5).
Singh J; Ling LE; Sawyer JS; Lee WC; Zhang F; Yingling JM
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):437-45. PubMed ID: 15338953
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of 5-(pyridin-2-yl)thiazoles as transforming growth factor-beta type1 receptor kinase inhibitors.
Kim DK; Choi JH; An YJ; Lee HS
Bioorg Med Chem Lett; 2008 Mar; 18(6):2122-7. PubMed ID: 18262787
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modeling and hybrid virtual screening for the discovery of novel IκB kinase 2 (IKK2) inhibitors.
Xie HZ; Liu LY; Ren JX; Zhou JP; Zheng RL; Li LL; Yang SY
J Biomol Struct Dyn; 2011 Aug; 29(1):165-79. PubMed ID: 21696232
[TBL] [Abstract][Full Text] [Related]
19. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
[TBL] [Abstract][Full Text] [Related]
20. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.
Gellibert F; Woolven J; Fouchet MH; Mathews N; Goodland H; Lovegrove V; Laroze A; Nguyen VL; Sautet S; Wang R; Janson C; Smith W; Krysa G; Boullay V; De Gouville AC; Huet S; Hartley D
J Med Chem; 2004 Aug; 47(18):4494-506. PubMed ID: 15317461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]